These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12881196)

  • 21. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phenotypic switching of VEGF and collagen XVIII during hypoxia in head and neck squamous carcinoma cells.
    Stewart J; Siavash H; Hebert C; Norris K; Nikitakis NG; Sauk JJ
    Oral Oncol; 2003 Dec; 39(8):862-9. PubMed ID: 13679210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
    Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
    Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma.
    Chen X; Ding G; Gao Q; Sun J; Zhang Q; Du L; Qiu Z; Wang C; Zheng F; Sun B; Ni J; Feng Z; Zhu J
    PLoS One; 2013; 8(5):e63093. PubMed ID: 23675455
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functionalized magnetic dextran-spermine nanocarriers for targeted delivery of doxorubicin to breast cancer cells.
    Tarvirdipour S; Vasheghani-Farahani E; Soleimani M; Bardania H
    Int J Pharm; 2016 Mar; 501(1-2):331-41. PubMed ID: 26875475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of a hydrophilic photosensitizer by use of internalizing monoclonal antibodies: A new possibility for use in photodynamic therapy.
    Vrouenraets MB; Visser GW; Loup C; Meunier B; Stigter M; Oppelaar H; Stewart FA; Snow GB; van Dongen GA
    Int J Cancer; 2000 Oct; 88(1):108-14. PubMed ID: 10962447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines.
    Elbayoumi TA; Torchilin VP
    Eur J Pharm Sci; 2007 Nov; 32(3):159-68. PubMed ID: 17707615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting doxorubicin to epidermal growth factor receptors by site-specific conjugation of C225 to poly(L-glutamic acid) through a polyethylene glycol spacer.
    Vega J; Ke S; Fan Z; Wallace S; Charsangavej C; Li C
    Pharm Res; 2003 May; 20(5):826-32. PubMed ID: 12751641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
    Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
    Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
    Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains.
    King HD; Dubowchik GM; Mastalerz H; Willner D; Hofstead SJ; Firestone RA; Lasch SJ; Trail PA
    J Med Chem; 2002 Sep; 45(19):4336-43. PubMed ID: 12213074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
    Takahashi H; Adachi K; Yamaguchi F; Teramoto A
    Anticancer Res; 1999; 19(5B):4151-5. PubMed ID: 10628367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic efficacy of a doxorubicin immunoconjugate in a preclinical model of spontaneous metastatic human melanoma.
    Sivam GP; Martin PJ; Reisfeld RA; Mueller BM
    Cancer Res; 1995 Jun; 55(11):2352-6. PubMed ID: 7757986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Star structure of antibody-targeted HPMA copolymer-bound doxorubicin: a novel type of polymeric conjugate for targeted drug delivery with potent antitumor effect.
    Kovár M; Strohalm J; Etrych T; Ulbrich K; Ríhová B
    Bioconjug Chem; 2002; 13(2):206-15. PubMed ID: 11906257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats.
    Sjögren HO; Isaksson M; Willner D; Hellström I; Hellström KE; Trail PA
    Cancer Res; 1997 Oct; 57(20):4530-6. PubMed ID: 9377565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity.
    Braslawsky GR; Kadow K; Knipe J; McGoff K; Edson M; Kaneko T; Greenfield RS
    Cancer Immunol Immunother; 1991; 33(6):367-74. PubMed ID: 1878890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PEG-doxorubicin conjugates: influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity.
    Veronese FM; Schiavon O; Pasut G; Mendichi R; Andersson L; Tsirk A; Ford J; Wu G; Kneller S; Davies J; Duncan R
    Bioconjug Chem; 2005; 16(4):775-84. PubMed ID: 16029018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HPMA copolymer-bound doxorubicin targeted to tumor-specific antigen of BCL1 mouse B cell leukemia.
    Kovár M; Mrkvan T; Strohalm J; Etrych T; Ulbrich K; Stastný M; Ríhová B
    J Control Release; 2003 Oct; 92(3):315-30. PubMed ID: 14568412
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody-Drug Conjugates.
    Kulkarni AA; Gukasyan HJ
    Pharm Res; 2015 Nov; 32(11):3451-2. PubMed ID: 26275530
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.